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software recently developed at NASA that is able to perform HF QRS analysis in real
time on a beat-to-beat basis. Results. The mean number of HF QRS leads (out of 12)
containing reduced amplitude zones (RAZs) of at least moderate severity was 8.4 + 2.1
in the cardiomyopathy patients versus 2.6 + 2.4 in the healthy controls (P<0.001). In addi-
tion, an HF QRS ECG scoring system that takes into consideration both the total number
of RAZs and the clustering of RAZs together in adjacent leads was 93.1% sensitive and
89.7% specific for identifying cardiomyopathy. The total amplitude of the HF QRS com-
plexes, as measured by summed root mean square voltages (RMSVs), also differed
between the individuals with versus without cardiomyopathy (35.9 + 12.1 vs. 43.8 + 15.8
microvolts respectively, P<0.02), although RMSV was less effective in distinguishing the
two groups than were RAZ scores because of large inter-subject variability in RMSV. In
the cardiomyopathy group, neither RAZ scores nor RMSVs directly correlated with
echocardiographic EF. Conclusion. 12-lead HF QRS ECG employing RAZ analysis is a
simple, sensitive and inexpensive screening technique for cardiomyopathy. It can be per-
formed at the same time as conventional 12-lead ECG, using the exact same equipment.
Although HF QRS ECG is highly sensitive for cardiomyopathy, its specificity may be com-
promised in patients with cardiac pathologies other than cardiomyopathy, such as
uncomplicated coronary artery disease. Further studies are required to determine the
usefulness of HF QRS for monitoring cardiomyopathy in a longitudinal fashion.
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Background: The NICaSTM is a novel non-invasive apparatus based on whole body
electrical bio-impedance for simple non-invasive continuous CO determination.
Patients and Methods: Patients were recruited while randomized in a study evaluating
the efficacy of Tezosentan (a ET-A/B endothelin antagonist) in patients admitted due to
acute heart failure (CHF). Patients were randomized after having been hospitalized due
to acute heart failure with dyspnea at rest, CI < 2.5 L/min/m2 and PCWP > 20 mmHg.
Study Protocol: At baseline and during treatment with study drug at the pre-specified
time points of 0.5,1,2,3,4 and 6 hours from randomization CO was determined by both
thermodilution and the NICaSTM 2001 apparatus. At each time point CO was determined
by thermodilution and NICaSTM 2001 apparatus by a two independed, blinded operators.
Results: Out of 130 patients enrolled, in 93 CO was measured simultaneously by both
methods at all the pre-determined time points. The overall Correlation between the two
methods was R=0.81. Precision and bias were 0.01±0.6 L/min. There was a difference
between the two methods in cardiac output readings. When Mean CI (of both methods)
was < 2 L/min/M2 CO readings were statistically significantly lower by NICaS while when
CI was >3 L/min/M2, CO readings were statistically significantly higher by NICaS. We
have calculated the cardiac power index (Cpi=CI* mean arterial pressure), and found that
low Cpi (indicating reduced myocardial contractile reserve) was related to higher recur-
rent CHF. However, Cpi based no NICaS CI measurement (NICaS Cpi) was a better pre-
dictor of recurrent CHF then thermodilution Cpi (Th Cpi), due to less accurate prediction
in patients with high Cpi.
Conclusions: NICaS is a novel accurate non-invasive method for CO determination. The
results of the present study suggest that NICaS is probably at least as accurate then
thermodilution for CO determination.
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Background: Studies from the pre-beta blocker era indicated that exercise cardiopulmo-
nary tests (CPX) predict prognosis in chronic systolic heart failure (HF). However, recent
studies have questioned the usefulness of these data for predicting prognosis in patients
treated with beta blockers.
Methods: We performed CPX in 209 consecutive patients in 1996 with mild – moderate
HF (mean EF 23%) followed for 19 ± 12 months for major clinical events (13 cardiac
deaths and 15 urgent transplantations) and assessed the prognostic impact of standard
CPX data in 64 patients treated with beta blockers (event rate 12.5%) and in 145 patients
not receiving beta blockers (event rate 13.8%).
Results: Both groups were similar for peak VO2, and peak VO2 corrected for lean body
weight, but patients on beta blockers had higher O2 pulse (11.0 ± 3.9 vs. 10.0 ± 4.0 ml/
beat; p=0.04) and O2 pulse lean (16.4 ± 6.0 vs. 14.4 ± 6.2ml/beat; p=0.02) which may be
important since O2 pulse lean was the strongest independent predictor of event-free sur-
vival (chi-square 12.4; p<0.001). Standard CPX data predicted prognosis considerably
better in patients not taking beta blockers compared with those on beta blockers (table).
However, in patients on beta blockers, peak VO2 of 14 ml/kg/min provided particularly
poor prognostic stratification and peak O2-pulse lean (cut-off 14 ml/beat) provided the
best prognostic stratification.
Conclusion: Standard CPX data need further refinement for providing risk stratification
for HF in the beta-blocker era.
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Background: Recent evidence suggests that adults with Marfan syndrome (MFS) have
diastolic dysfunction due to abnormal elastic recoil of the fibrillin-containing myocardial
interstitium. We sought to assess diastolic function in a large group of children and young
adults with MFS in order to determine whether diastolic dysfunction is present in all
patients or it is an age-related phenomenon.We also sought to assess the relationship
between % predicted aortic root size and the diastolic performance. Methods: Echocar-
diographic review of all 40 patients with MFS diagnosed in accordance with the revised
Gent criteria was performed. The last echocardiogram performed prior to initiation of car-
diac medical therapy was analyzed. Patients with more than trivial mitral or aortic regurgi-
tation, or with prior cardiovascular surgical intervention were excluded from the study.
Echocardiograms on a group of 40 age-matched normal controls with no family history of
MFS were used for comparison. The correlation between % predicted left ventricular end
diastolic diameter [LVEDd], % predicted aortic root size, and diastolic parameters [mitral
valve (MV) inflow: MV E/A, MV deceleration time (DT), and isovolumic relaxation time
(IVRT)] were determined. Results: There was no difference in age (yr) (17.4 ± 11.7 vs
13.9 ± 9.0, p= 0.14), sex (male 60% vs 50%, p= 0.38) or body surface area (1.47 ± 0.38
vs 1.33 ± 0.39, p= 0.09) between MFS patients and controls. Patients with MFS had sig-
nificantly impaired diastolic performance with both impaired relaxation and increased wall
stiffness as evidenced by prolonged DT (175 ± 69.2 ms vs 142 ± 27.5 ms, p= 0.007) &
IVRT (72 ± 23 ms vs 54 ± 11 ms, p = 0.0003). MV E (81± 23 ms), MV A (45± 10 ms), and
MV E/A (1.8 ± 0.6 ms) in MFS patients were within normal limits. There was no relation-
ship between % predicted aortic root size or % LVEDd and diastolic performance (for MV
E/A, r = 0.26 and 0.03; for IVRT, r = 0.13 and 0.17; and for DT, r = 0.09 and 0.06). Con-
clusion: Diastolic dysfunction is a clinical feature of MFS even in a younger cohort of
patients. Impairment of diastolic function may be secondary to abnormal myocardial elas-
tic recoil or altered afterload conditions in the face of increased aortic wall stiffness.
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Background: Electrocardiography (ECG), signal averaged ECG (SAECG), exercise tol-
erance testing (ETT) Holter monitoring (Hol) and magnetic resonance imaging (MRI) are
commonly employed in the evaluation of patients suspected of having ARVD. Each of
these is widely available with the exception of MRI. We sought to determine if MRI pro-
vided incremental information to that obtained with the more widely available tests.
Methods: We evaluated 58 (26 male) patients referred for evaluation of possible ARVD.
Each patient underwent ECG, SAECG, ETT, Hol and MRI. Each test was rated as posi-
tive or negative for ARVD. The diagnosis of ARVD was established by International Task
Force Criteria. The sensitivity (Se) and specificity (Sp) for each test was calculated.
Receiver operating curve (ROC) analysis was used to evaluate the combination of ECG,
SAECG, Hol and ETT and their combination with MRI.
Results: The ECG (Se=96% Sp=78%) showed maximum utility in diagnosis of ARVD as
compared to SAECG (Se=22% Sp=94%), ETT (Se=22% Sp=88%), Hol (Se=67%
Predicting Major Clinical Events
Peak Variable Beta Blocker 
(n=64; 8 
events)
P-Value No Beta 
Blocker 
(n=145; 20 
events)
P-Value
VO2 >= 14 ml/kg/min 4/40 (10%) =0.48 6/83 (7%) =0.01
VO2 < 14 ml/kg/min 4/24 (17%) 14/62 (23%)
VO2 lean >= 19 ml/kg/min 3/39 (8%) =0.18 4/85 (5%) <0.001
VO2 lean < 19 ml/kg/min 5/25 (20%) 16/60 (27%)
O2 pulse >= 10 ml/beat 4/44 (9%) =0.26 5/75 (6%) =0.01
O2 pulse < 10 ml/beat 4/20 (20%) 15/70 (21%)
O2 pulse lean >= 14 ml/beat 3/41 (7%) =0.10 2/72 (3%) <0.0001
O2 pulse lean < 14 ml/beat 5/23 (22%) 18/73 (25%)
